Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Mitochondria-Boosting drug help save sight in glaucoma?

NCT ID NCT06437639

Disease control Sponsor: Pharmasoft Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested the drug Mexidol in 80 people with advanced primary open-angle glaucoma. The goal was to see if the drug could improve the function of mitochondria in cells and protect the optic nerve. Participants were randomly assigned to receive Mexidol or standard care, and researchers measured changes in cell energy levels and vision over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mexidol (ethylmethylhydroxypyridine succinate)
What this could lead to
If it works, this could point toward a way to protect the optic nerve in glaucoma patients, potentially slowing vision loss.
What could go wrong
This is a small, completed Phase 4 trial with only 80 participants, so results may not apply to everyone. The main focus is on cell-level changes, not direct vision improvement, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

80 people

The number who actually took part.

Started

Sep 2023

Finished

Feb 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * An advanced stage of POAG in one or two eyes * Hypotonic-compensated intraocular pressure (IOP) Exclusion Criteria: * Degenerative diseases of the central nervous system, diabetes mellitus * Primary mitochondrial dysfunction * A history of surgical interventions and damage to the organ of vision * Acute or chronic inflammatory or hereditary degenerative eye diseases (anterior and posterior sections) * Decompensation of concomitant somatic diseases * Taking antioxidants/nootropic drugs 6 months before inclusion in the study * Hypersensitivity to ethylmethylhydroxypyridine succinate or to any of the excipients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary open angle glaucoma (POAG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma inborn mitochondrial metabolism disorder open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary open angle glaucoma (POAG)

Contacts and locations

Locations

  • Tyumen Scientific Center of the Russian Academy of Sciences

    Tyumen, Russian Federation, 625026, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.